Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval

Celgene said Monday it has again sent the FDA an application for approval of ozanimod, an experimental multiple sclerosis drug it added to its pipeline in 2015 as part of its $7.2 billion acquisition of San Diego?s Receptos. Just over a year ago, the FDA refused to review Celgene?s application for ozanimod, citing a lack [?]